Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter P Toth

Showing results (161-170 of 425) with videos related to

Pageof 43
Sort By:
Diabetes, Obesity & Metabolism|November 20, 2019
Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidencePeter P Toth, Sergio Fazio, Nathan D Wong, et al.
American Heart Journal Plus : Cardiology Research and Practice|April 1, 2024
Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studiesArrigo F G Cicero, Federica Fogacci, Alberto Zambon, et al.
Journal of the American Heart Association|October 30, 2018
High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular RiskPeter P Toth, Craig Granowitz, Michael Hull, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|May 21, 2014
Should low high-density lipoprotein cholesterol (HDL-C) be treated?Peter P Toth, Marcin Barylski, Dragana Nikolic, et al.
Current Pharmaceutical Design|September 18, 2013
Statins and new-onset diabetesMarcin Barylski, Dragana Nikolic, Maciej Banach, et al.
Future Cardiology|September 22, 2020
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reductionWilliam E Boden, Seth Baum, Peter P Toth, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|May 21, 2014
Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionalityMarcin Barylski, Peter P Toth, Dragana Nikolic, et al.
Plos One|April 6, 2012
Achieving secondary prevention low-density lipoprotein particle concentration goals using lipoprotein cholesterol-based dataSimon C Mathews, Jaya Mallidi, Krishnaji Kulkarni, et al.
Pancreas|August 13, 2016
All-Cause and Acute Pancreatitis Health Care Costs in Patients With Severe HypertriglyceridemiaNazia Rashid, Puza P Sharma, Ronald D Scott, et al.
BMJ (Clinical Research Ed.)|May 23, 2014
Taking a longer term view of cardiovascular risk: the causal exposure paradigmAllan D Sniderman, Peter P Toth, George Thanassoulis, et al.
Pageof 43

Showing results (161-170 of 425) with videos related to

Sort By:
Pageof 43
Diabetes, Obesity & Metabolism|November 20, 2019
Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidencePeter P Toth, Sergio Fazio, Nathan D Wong, et al.
American Heart Journal Plus : Cardiology Research and Practice|April 1, 2024
Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studiesArrigo F G Cicero, Federica Fogacci, Alberto Zambon, et al.
Journal of the American Heart Association|October 30, 2018
High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular RiskPeter P Toth, Craig Granowitz, Michael Hull, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|May 21, 2014
Should low high-density lipoprotein cholesterol (HDL-C) be treated?Peter P Toth, Marcin Barylski, Dragana Nikolic, et al.
Current Pharmaceutical Design|September 18, 2013
Statins and new-onset diabetesMarcin Barylski, Dragana Nikolic, Maciej Banach, et al.
Future Cardiology|September 22, 2020
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reductionWilliam E Boden, Seth Baum, Peter P Toth, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|May 21, 2014
Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionalityMarcin Barylski, Peter P Toth, Dragana Nikolic, et al.
Plos One|April 6, 2012
Achieving secondary prevention low-density lipoprotein particle concentration goals using lipoprotein cholesterol-based dataSimon C Mathews, Jaya Mallidi, Krishnaji Kulkarni, et al.
Pancreas|August 13, 2016
All-Cause and Acute Pancreatitis Health Care Costs in Patients With Severe HypertriglyceridemiaNazia Rashid, Puza P Sharma, Ronald D Scott, et al.
BMJ (Clinical Research Ed.)|May 23, 2014
Taking a longer term view of cardiovascular risk: the causal exposure paradigmAllan D Sniderman, Peter P Toth, George Thanassoulis, et al.
Pageof 43